<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9890">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710762</url>
  </required_header>
  <id_info>
    <org_study_id>1199.9</org_study_id>
    <secondary_id>EUDRACT2005-002427-14</secondary_id>
    <nct_id>NCT00710762</nct_id>
    <nct_alias>NCT00370175</nct_alias>
  </id_info>
  <brief_title>A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer</brief_title>
  <official_title>A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Great Britain: MHRA</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to estimate the Progression Free Survival Rates (PFS)
      of patients with relapsed ovarian cancer after 9 months of continuous treatment with either
      BIBF 1120 or matching placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>PFS Rate at 36 Weeks (After 9 Months)</measure>
    <time_frame>36 weeks (after 9 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)</measure>
    <time_frame>12 weeks (after 3 months) and 24 weeks ( after 6 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumour Progression</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels.
For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria:
Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart.
Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This end point was not determined as no patients died during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Intensity of Adverse Events With Grading According CTCAE</measure>
    <time_frame>First drug administration until 28 days after last drug administration,up until 309 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Laboratory Parameters</measure>
    <time_frame>First drug administration until 28 days after last drug administration, up until 309 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.</description>
  </secondary_outcome>
  <enrollment type="Actual">89</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF1120</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with histologically confirmed advanced ovarian carcinoma, fallopian
             tube carcinoma or primary peritoneal cancer of serous type with recurrent disease and
             who responded to 2nd, 3rd or 4th line chemotherapy. Response is defined as either a
             confirmed decline in CA125 of at least 50% from the pre-treatment value or an
             Objective Response, i.e. a Partial Response (PR) or Complete Response (CR) according
             to the RECIST criteria in patients with measurable disease.

          -  Treatment-free interval of &lt; 12 months since commencing prior treatment regimen for
             relapsed ovarian cancer.

          -  Full recovery from all therapy related toxicities of previous chemotherapy and or
             radiotherapy or recovery in as much as no further improvement may be expected by the
             investigator.

          -  Age &gt; 18 years.

          -  Life expectancy of at least 3 months.

          -  ECOG Performance Score &lt; 2.

          -  Adequate hepatic function: total bilirubin 26µmol/L, ALT and/or AST 1.5x upper limit
             of normal (ULN). INR, Prothrombin time (PT) and partial thromboplastin time (PTT):
             maximum 50% deviation from normal limits.

          -  Adequate renal function: serum creatinine 1.5 x ULN.

          -  Absolute neutrophil count (ANC) &gt;1.5 x 109l, Platelets &gt; 100 x 109/l, Haemoglobin &gt;
             9.0 g/dl.

          -  Written informed consent consistent with ICH-GCP guidelines.

          -  Minimum time elapsed since last chemotherapy (including hormonal treatment other than
             Hormone Replacement Therapy [HRT]) or immunotherapy and the first administration of
             BIBF 1120 must be more than 4 but less than 8 weeks.

        Exclusion Criteria:

          -  Serious illness or concomitant non-oncological disease such as neurologic,
             psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or
             laboratory abnormality that may increase the risk associated with study participation
             or study drug administration and in the judgment of the investigator would make the
             patient inappropriate for entry into the study.

          -  Major injuries and/or surgery within past 4 weeks with incomplete wound healing or
             bone fracture and planned surgical procedures during the study period.

          -  Hypersensitivity to BIBF 1120 or the excipients of the study drug.

          -  Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina,
             history of infarction within past 9 months, congestive heart failure &gt; NYHA II).

          -  History of haemorrhagic or thrombotic event in the past 12 months. Known inherited
             predisposition to bleeds or to thrombosis.

          -  Patients who require full-dose anticoagulation.

          -  Gastrointestinal disorders or abnormalities that would inhibit absorption of the
             study drug.

          -  Brain metastases or leptomeningeal disease.

          -  Treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial.

          -  Chemo-, radio-, or immunotherapy within the past four weeks prior to treatment with
             the trial drug.

          -  Patients unable to comply with the protocol.

          -  Active alcohol or drug abuse.

          -  Other documented malignancy with the exception of non-melanomatous skin cancer within
             the past 5 years.

          -  Patients who are not clinically sterile.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.9.4413 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burton on Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Creigiau, Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4410 St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.9.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 16, 2015</lastchanged_date>
  <firstreceived_date>July 3, 2008</firstreceived_date>
  <firstreceived_results_date>November 14, 2014</firstreceived_results_date>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>89 patients were enrolled and 84 patients were randomised for this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nintedanib</title>
          <description>Patients were treated with 250mg nintedanib twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients were treated with matching placebo twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event other disease worsening</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason other than listed above</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set consist of all patients who received at least 1 dose of nintedanib or placebo.
Note: 43 patients were included in the analyses instead of 44 patients in nintedanib arm as one patient was excluded after drug administration due to important protocol violation.</population>
      <group_list>
        <group group_id="B1">
          <title>Nintedanib</title>
          <description>Patients were treated with 250mg nintedanib twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients were treated with matching placebo twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="83"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58.4" spread="9.5"/>
                <measurement group_id="B2" value="61.3" spread="9.1"/>
                <measurement group_id="B3" value="59.8" spread="9.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="83"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PFS Rate at 36 Weeks (After 9 Months)</title>
        <description>The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.</description>
        <time_frame>36 weeks (after 9 months)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib</title>
            <description>Patients were treated with 250mg nintedanib twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>PFS Rate at 36 Weeks (After 9 Months)</title>
            <description>The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.</description>
            <units>percent probability of PFS</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15.6" lower_limit="3.8" upper_limit="27.3"/>
                  <measurement group_id="O2" value="2.9" lower_limit="0.0" upper_limit="8.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)</title>
        <description>The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.</description>
        <time_frame>12 weeks (after 3 months) and 24 weeks ( after 6 months)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib</title>
            <description>Patients were treated with 250mg nintedanib twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)</title>
            <description>The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability.</description>
            <units>percent probability of PFS</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>at 24 weeks ( after 6 months)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.7" lower_limit="12.5" upper_limit="40.8"/>
                  <measurement group_id="O2" value="17.3" lower_limit="5.2" upper_limit="29.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>at 12 weeks (after 3 months)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45.3" lower_limit="29.5" upper_limit="61.2"/>
                  <measurement group_id="O2" value="46.2" lower_limit="30.5" upper_limit="61.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumour Progression</title>
        <description>Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels.
For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria:
Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart.
Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD.</description>
        <time_frame>9 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib</title>
            <description>Patients were treated with 250mg nintedanib twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Tumour Progression</title>
            <description>Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels.
For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria:
Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart.
Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD.</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>according to RECIST and CA-125</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83.00" lower_limit="78.0" upper_limit="149.0"/>
                  <measurement group_id="O2" value="84.00" lower_limit="78.0" upper_limit="87.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>according to CA-125</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85.00" lower_limit="79.0" upper_limit="149.0"/>
                  <measurement group_id="O2" value="86.00" lower_limit="67.0" upper_limit="113.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>according to RECIST</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="143.0" lower_limit="82.0" upper_limit="175.0"/>
                  <measurement group_id="O2" value="85.0" lower_limit="78.0" upper_limit="89.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death</title>
        <description>This end point was not determined as no patients died during the trial.</description>
        <time_frame>9 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>This endpoint could not be calculated as no patients died.</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib</title>
            <description>Patients were treated with 250mg nintedanib twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Death</title>
            <description>This end point was not determined as no patients died during the trial.</description>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Intensity of Adverse Events With Grading According CTCAE</title>
        <description>Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).</description>
        <time_frame>First drug administration until 28 days after last drug administration,up until 309 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib</title>
            <description>Patients were treated with 250mg nintedanib twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence and Intensity of Adverse Events With Grading According CTCAE</title>
            <description>Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CTCAE grade 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="25.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CTCAE grade 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34.9"/>
                  <measurement group_id="O2" value="42.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CTCAE grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53.5"/>
                  <measurement group_id="O2" value="25.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CTCAE grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CTCAE grade 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Laboratory Parameters</title>
        <description>Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.</description>
        <time_frame>First drug administration until 28 days after last drug administration, up until 309 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib</title>
            <description>Patients were treated with 250mg nintedanib twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients were treated with matching placebo twice daily</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Relevant Abnormalities for Laboratory Parameters</title>
            <description>Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.2"/>
                  <measurement group_id="O2" value="7.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.2"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.6"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0"/>
                  <measurement group_id="O2" value="5.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.7"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood alkaline phosphatase abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lymphocyte count decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vitamin B12 decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine aminotransferase abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood lactate dehydrogenase abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gamma-glutamyltransferase abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neutrophil count decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White blood cells urine positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood pressure increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Electrocardiogram T wave amplitude decreased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="2.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Liver function test abnormal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.3"/>
                  <measurement group_id="O2" value="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First drug administration until 28 days after last drug administration, up until 309 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nintedanib</title>
          <description>Patients were treated with 250mg nintedanib twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients were treated with matching placebo twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data from all randomised patients collected upto NOV’08 were included in all above sections,unless stated otherwise.5 patients continued on BIBF1120 after database lock(DBL)-NOV’08 upto Mar’14,but due to limited data no further analyses were done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
